TOPICAL TRIAMCINOLONE ACETONIDE IN RECURRENT APHTHOUS STOMATITIS A Clinical Trial

Browne, R.M.; Fox, E. C.; Anderson, R. J.

doi:10.1016/s0140-6736(68)92833-x

Cited by 19 publications

(8 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…24,25 Two non-placebo controlled trials found no significant differences between triamcinolone ointment or betamethasone tablets and adhesive vehicles (Biobase [no longer available] and Orabase [Colgate-Hoyt]) in the frequency and duration of severe RAU. 26,27 Subjective improvement tended to be greater with corticosteroids than with adhesive vehicle (Orabase), although the difference was not statistically significant. 27 A singleblind, placebo-controlled trial involving fluocinonide ointment was performed in patients with minor and major RAU.…”

Section: Corticosteroidsmentioning

confidence: 88%

Treatment strategies for recurrent oral aphthous ulcers

Barrons

2001

American Journal of Health-System Pharmacy

137

View full text Add to dashboard Cite

A phthous ulcers are among the most common oral lesions in the general population, with a frequency of 5-25% and threemonth recurrence rates as high as 50%. 1 Aphthous ulcers have been reported in 2-4% of HIV-seropositive patients, although these patients suffer from larger and more frequent aphthae in advanced stages of their disease. 2 Aphthous ulcers are often quite painful; may lead to difficulty in speaking, eating, and swallowing; and may negatively affect patients' quality of life. 2,3 In patients with advanced HIV disease, aphthous ulcers may exacerbate weight loss. While most aphthae are small and heal within 7-10 days, larger ulcers can persist for weeks or months. Consequently, therapy for the disease of recurrent aphthous ulcers (RAU) should address both healing and the prevention of new ulcers. This article reviews the clinical features and etiology of RAU in HIVseropositive and HIV-seronegative persons; the mechanisms of action, efficacy, and safety of medications used to treat RAU; and the recommended therapeutic strategies. The studies that provided the basis for

show abstract

Section: Corticosteroidsmentioning

confidence: 88%

Treatment strategies for recurrent oral aphthous ulcers

Barrons

2001

American Journal of Health-System Pharmacy

137

View full text Add to dashboard Cite

show abstract

“…Only one crossover, randomized controlled trial demonstrated a significant reduction in pain compared with placebo, but showed no effect on reducing the frequency of RAU occurrence (19). The remaining studies give some weak evidence of a reduction in pain and ulcer duration, without significant adverse effects (20–25). It was also reported that most users preferred topical steroids to control preparations (21–24).…”

Section: Discussionmentioning

confidence: 99%

“…The remaining studies give some weak evidence of a reduction in pain and ulcer duration, without significant adverse effects (20–25). It was also reported that most users preferred topical steroids to control preparations (21–24). The evidence, therefore suggests that topical steroids are of value to this group of patients.…”

Section: Discussionmentioning

confidence: 99%

The efficacy of topical hyaluronic acid in the management of recurrent aphthous ulceration

Nolan

Baillie

Badminton

et al. 2006

J Oral Pathology Medicine

View full text Add to dashboard Cite

show abstract

“…Corticosteroids Though there are few well‐controlled randomized, controlled trials, topical corticosteroids may reduce ulcer pain and speed healing (147). Mouth rinses, ointments, creams, gels, pastes, or adhesive vehicles are available and many are effective in the control of RAS (148–162), but the major concern is of adrenal suppression with long‐term or repeated application. However, there is little evidence that even some of the more potent steroids, such as fluocinonide and betamethasone‐17‐valerate, can cause any significant problem in this respect (161,162).…”

mentioning

confidence: 99%

Aphthous ulcerations

2002

View full text Add to dashboard Cite

Recurrent aphthous stomatitis (RAS) is a chronic condition, usually with a childhood or adolescent onset and with a tendency to diminish in frequency and severity with age. Most patients are otherwise healthy. The differential diagnosis for “aphthae” includes vesiculobullous diseases, granulomas, and even squamous cell carcinomas. The onset of aphthous‐like lesions in adults suggests the possibility of developing a more complex systemic disorder such as Behcet's syndrome or inflammatory bowel disease. Treatment includes correction of underlying diseases or predisposing causes, and the use of topical and systemic anti‐inflammatory agents or immunomodulating drugs.

show abstract

TOPICAL TRIAMCINOLONE ACETONIDE IN RECURRENT APHTHOUS STOMATITIS A Clinical Trial

Cited by 19 publications

References 7 publications

Treatment strategies for recurrent oral aphthous ulcers

Treatment strategies for recurrent oral aphthous ulcers

The efficacy of topical hyaluronic acid in the management of recurrent aphthous ulceration

Aphthous ulcerations

Contact Info

Product

Resources

About